Ultragenyx Pharmaceutical
RARE
Market cap $3.5B

37.49 USD

-1.80

4.58%

At close Jun 13, 4:00 PM EDT

After hours

37.49

+0.00

0.00%

1 day

-4.58%

5 days

-0.92%

1 month

5.90%

3 months

-4.48%

6 months

-18.11%

Year to date

-8.89%

1 year

-13.06%

5 years

-45.83%

10 years

-57.71%

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 4 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

40% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 7 (+2) [Q1 2025]

20% more repeat investments, than reductions

Existing positions increased: 125 | Existing positions reduced: 104

1.27% more ownership

Funds ownership: 94.76% [Q4 2024] → 96.02% (+1.27%) [Q1 2025]

4% more call options, than puts

Call options by funds: $43.9M | Put options by funds: $42.2M

5% less funds holding

Funds holding: 310 [Q4 2024] → 296 (-14) [Q1 2025]

13% less capital invested

Capital invested by funds: $3.68B [Q4 2024] → $3.22B (-$463M) [Q1 2025]

25% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 44

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$65

73%

upside

Avg. target

$91

141%

upside

High target

$117

212%

upside

4 analyst ratings

4 positive

100%

0 neutral

0%

0 negative

0%

William Blair Sami Corwin	73%upside $65	Outperform Initiated	28 May 2025
Morgan Stanley Jeffrey Hung	73%upside $65	Overweight Maintained	9 May 2025
JP Morgan Anupam Rama	212%upside $117	Overweight Maintained	27 Mar 2025
Piper Sandler Allison Bratzel	207%upside $115	Overweight Maintained	17 Mar 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

NOVATO, Calif., June 03, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's chief executive officer, will participate in a fireside at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025, at 10:00 a.m. ET.

Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare Conference

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves.

Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact Report

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

NOVATO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's chief financial officer and executive vice president, will participate in a fireside at Bank of America's 2025 Healthcare Conference on Tuesday, May 13, 2025, at 8:00 a.m. PT.

Ultragenyx to Participate at Bank of America's 2025 Healthcare Conference

Zacks Investment Research

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y

RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.

Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Ultragenyx (RARE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx (RARE) came out with a quarterly loss of $1.57 per share versus the Zacks Consensus Estimate of a loss of $1.54. This compares to loss of $2.03 per share a year ago.

Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

First quarter total revenue of $139 million, Crysvita® revenue of $103 million and Dojolvi® revenue of $17 million

Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update

Zacks Investment Research

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

See News Rankings

Charts implemented using Lightweight Charts™